DPP (IV) inhibitors have emerged as a new class of oral antidiabetic agents. These inhibitors promote glucose homeostasis by inhibiting degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) by DPP (IV). GLP-1 extends the action of insulin while suppressing the release of glucagon. Cayman’s DPP (IV) Inhibitor Screening Assay provides a convenient fluorescence-based method for screening DPP (IV) inhibitors in a 96-well format.

DPP (IV) Inhibitor Screening Assay Kit – 96 wells

Brand:
Cayman
Storage:
-80

DPP (IV) inhibitors have emerged as a new class of oral antidiabetic agents. These inhibitors promote glucose homeostasis by inhibiting degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) by DPP (IV). GLP-1 extends the action of insulin while suppressing the release of glucagon. Cayman’s DPP (IV) Inhibitor Screening Assay provides a convenient fluorescence-based method for screening DPP (IV) inhibitors in a 96-well format.  

 

Available on backorder

Add to quotes
SKU: 700210 - 96 wells Category:

Description

DPP (IV) inhibitors have emerged as a new class of oral antidiabetic agents. These inhibitors promote glucose homeostasis by inhibiting degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) by DPP (IV). GLP-1 extends the action of insulin while suppressing the release of glucagon. Cayman’s DPP (IV) Inhibitor Screening Assay provides a convenient fluorescence-based method for screening DPP (IV) inhibitors in a 96-well format.

Formulation:

Formal name:

Synonyms:  Dipeptidyl peptidase IV

Host:

Imunogen:

Applications: 

Clone:

Purity:

Origin:

Product Type|Assay Kits|Fluorometric Assays||Product Type|Assay Kits|Inhibitor Screening Assays||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes

Related products